Helix BioPharma (TSE:HBP) Shares Cross Above Fifty Day Moving Average - Should You Sell?

Key Points

• Helix BioPharma's stock price has surpassed its fifty-day moving average of C$1.08, reaching a high of C$1.33 during trading.
• Despite this increase, the stock is currently down 1.5% and last traded at C$1.30, with a market cap of C$68.93 million.
• The company is focused on cancer drug development, particularly in immuno-oncology, and is developing therapies like Tumor Defence Breaker L-DOS47 and V-DOS47.

Helix BioPharma Corp. (TSE:HBP - Get Free Report) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$1.08 and traded as high as C$1.33. Helix BioPharma shares last traded at C$1.30, with a volume of 6,200 shares traded.

Helix BioPharma Stock Performance

The firm has a market cap of C$100.85 million, a price-to-earnings ratio of -1.32 and a beta of -0.62. The business's 50 day moving average price is C$1.09 and its 200 day moving average price is C$0.95.

About Helix BioPharma

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.